Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers.

@article{Sannita1987EffectsOS,
  title={Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers.},
  author={W. Sannita and L. Maggi and G. Rosadini},
  journal={Neuropsychobiology},
  year={1987},
  volume={17 4},
  pages={
          199-205
        }
}
There has been clinical and experimental evidence that cholinergic compounds and precursors of choline are potentially useful in the treatment of dementia. Anticholinergic compounds have also been proposed as a possible acute model for pharmaco-EEG studies focussed on CNS aging. Single doses of scopolamine (0.25-0.75 mg i.m.) and a matching placebo were administered to 8 young healthy volunteers. Quantitative EEG recordings and neuropsychological testing were performed in baseline conditions… Expand
EEG Changes following Scopolamine Administration in Healthy Subjects
Human flash-VEP and quantitative EEG are independently affected by acute scopolamine.
Pharmaco-EEG: A History of Progress and a Missed Opportunity
...
1
2
3
4
5
...